ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Tward on Abbreviated Course ADT for Prostate Cancer

Jonathan Tward, MD, PhD
Published: Friday, Jan 23, 2015


Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.
 
A recent study, presented at the annual meeting of the American Society for Radiation Therapy (ASTRO), in San Francisco, found that when given along with radiation therapy to men with high-risk prostate cancer, 18 months of ADT generated similar long-term outcomes and resulted in better quality of life when compared to the standard 36-month course.
 
The idea that 18 months of ADT can be as effective as 36 months is intriguing, says Tward, but the study has some flaws. However, based on these findings, Tward aims to do long-term ADT therapy, but counsels patients that are experiencing a reduced quality of life after 18 months to discontinue ADT.  

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.
 
A recent study, presented at the annual meeting of the American Society for Radiation Therapy (ASTRO), in San Francisco, found that when given along with radiation therapy to men with high-risk prostate cancer, 18 months of ADT generated similar long-term outcomes and resulted in better quality of life when compared to the standard 36-month course.
 
The idea that 18 months of ADT can be as effective as 36 months is intriguing, says Tward, but the study has some flaws. However, based on these findings, Tward aims to do long-term ADT therapy, but counsels patients that are experiencing a reduced quality of life after 18 months to discontinue ADT.  



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x